ArticleScientific reports2022
Evaluating approved and alternative treatments against an oxytetracycline-resistant bacterium responsible for European foulbrood disease in honey bees.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Evaluating efficacy of oxytetracycline, lincomycin, and tylosin for treatment of clinical European foulbrood disease.Journal of insect science (Online) · 2026Article
- In Vivo and In Vitro Evaluation of Probiotic and Postbiotic Strategies Against Foulbrood in Honeybees.Probiotics and antimicrobial proteins · 2026Article
- Divergent microbiome signatures between managed and wild honey bee (Microbiology spectrum · 2026Article
- Article
- Potential confounding factors in currently used antibiotic susceptibility assays for the honey bee pathogenJournal of medical microbiology · 2025Article
- Impact of different culture media and drying treatment on the isolation of Melissococcus plutonius, the causative agent of European foulbrood, from honey bee larval specimens.The Journal of veterinary medical science · 2025Article
- Nisin A Treatment to Protect Honey Bee Larvae from European Foulbrood Disease.Probiotics and antimicrobial proteins · 2025Article
- Unintended consequences of antibiotic use in beekeeping: drone health as a potential vulnerability.Animal microbiome · 2025Article
- Image-based honey bee larval viral and bacterial diagnosis using machine learning.Scientific reports · 2025Article
- Article
- Selection of Probiotics for Honey Bees: The In Vitro Inhibition ofMicroorganisms · 2025Article
- Antibiotic Use in Beekeeping: Implications for Health and Environment from a One-Health Perspective.Antibiotics (Basel, Switzerland) · 2025Article
- Disruption of collective behaviour correlates with reduced interaction efficiency.Proceedings. Biological sciences · 2025Article
- Antimicrobial control and temporal dynamics of M. plutonius colonization in adult worker honey bees (Apis mellifera).PloS one · 2025Article
- Probiotics and postbiotics: a promising prophylactic measure for American foulbrood and European foulbrood diseases of honey bees.Veterinary research forum : an international quarterly journal · 2025Article
- Viral adaptations to alternative hosts in the honey bee pathogenbioRxiv : the preprint server for biology · 2024Article
- IPM Strategy to Control EFB inVeterinary sciences · 2024Article
- Revisiting the role of pathogen diversity and microbial interactions in honeybee susceptibility and treatment ofFrontiers in veterinary science · 2024Review
- Article
- Identification of peptides from honeybee gut symbionts as potential antimicrobial agents against Melissococcus plutonius.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
European foulbrood (EFB) is a disease of honey bee larvae caused by Melissococcus plutonius. In North America, oxytetracycline (OTC) is approved to combat EFB disease though tylosin (TYL) and lincomycin (LMC) are also registered for use against American foulbrood disease. Herein, we report and characterize an OTC-resistant M. plutonius isolate from British Columbia, Canada, providing an antimicrobial sensitivity to the three approved antibiotics and studying their abilities to alter larval survival in an in vitro infection model. Specifically, we investigated OTC, TYL, and LMC as potential treatment options for EFB disease using laboratory-reared larvae infected with M. plutonius. The utility of the three antibiotics were compared through an experimental design that either mimicked metaphylaxis or antimicrobial intervention. At varying concentrations, all three antibiotics prevented clinical signs of EFB disease following infection with M. plutonius 2019BC1 in vitro. This included treatment with 100 μg/mL of OTC, a concentration that was ~ 3× the minimum inhibitory concentration measured to inhibit the strain in nutrient broth. Additionally, we noted high larval mortality in groups treated with doses of OTC corresponding to ~ 30× the dose required to eliminate bacterial growth in vitro. In contrast, TYL and LMC were not toxic to larvae at concentrations that exceed field use. As we continue to investigate antimicrobial resistance (AMR) profiles of M. plutonius from known EFB outbreaks, we expect a range of AMR phenotypes, reiterating the importance of expanding current therapeutic options along with alternative management practices to suppress this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.